Raolat M. Abdulai

Intensive Care Medicine

75 Francis St
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.

Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.

Journal: EClinicalMedicine

Published: March 20, 2026

Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis.

Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis.

Journal: The American journal of gastroenterology

Published: November 19, 2024

Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores.

Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores.

Journal: Respiratory medicine

Published: November 19, 2024

Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.

Effect of Dupilumab on Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS.

Journal: Chest

Published: October 10, 2024

Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).

Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).

Journal: Respiratory medicine

Published: August 26, 2024

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.

Journal: The Lancet. Respiratory medicine

Published: August 15, 2024

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Published: August 02, 2024

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.

Journal: The New England journal of medicine

Published: May 20, 2024

Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.

Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial.

Journal: The Lancet. Respiratory medicine

Published: April 05, 2024

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.

Journal: ERJ open research

Published: September 28, 2023

IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels.

IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels.

Journal: American journal of respiratory and critical care medicine

Published: September 14, 2023

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.

Journal: The New England journal of medicine

Published: June 05, 2023

Showing 1-12 of 20

Last Updated: 09/26/2026